1. Home
  2. VRAX vs SNGX Comparison

VRAX vs SNGX Comparison

Compare VRAX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.36

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.41

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
SNGX
Founded
2013
1987
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
13.8M
IPO Year
2022
1987

Fundamental Metrics

Financial Performance
Metric
VRAX
SNGX
Price
$0.36
$1.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$6.00
AVG Volume (30 Days)
908.5K
455.1K
Earning Date
01-01-0001
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,986.00
N/A
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$1.09
52 Week High
$3.20
$6.23

Technical Indicators

Market Signals
Indicator
VRAX
SNGX
Relative Strength Index (RSI) 44.43 48.55
Support Level $0.31 $1.31
Resistance Level $0.51 $1.45
Average True Range (ATR) 0.05 0.10
MACD -0.00 -0.00
Stochastic Oscillator 35.19 43.43

Price Performance

Historical Comparison
VRAX
SNGX

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: